Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 10/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.44 |
| ▸ | EPX | P11678 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594905 | 0.88 | MPO (0.61) | KMT2AMEN1MPOTPOEPX | |
| SCHEMBL19282316 | 0.86 | MPO (0.66) | KMT2AMEN1MPOMAPK1TPO | |
| SCHEMBL20429882 | 0.86 | SMN1; SMN2 (0.46) | KMT2AMPOGAATPOEPX | |
| SCHEMBL19282248 | 0.85 | MPO (0.61) | MPOTPOEPXALDH1A1HPGD | |
| SCHEMBL19294221 | 0.83 | NPC1 (0.50) | MPOTPOEPX | |
| SCHEMBL19282290 | 0.83 | MPO (0.58) | KMT2AMEN1MPOTPOEPX | |
| SCHEMBL19282315 | 0.83 | MPO (0.66) | KMT2AMEN1MPO | |
| SCHEMBL19294244 | 0.82 | MPO (0.50) | KMT2AMEN1MPOTPOEPX | |
| SCHEMBL19282273 | 0.82 | MPO (0.55) | KMT2AMEN1MPO | |
| SCHEMBL19294223 | 0.82 | MPO (0.44) | MPOTPOEPX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | claimed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | claimed |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-31 | — | — | US | disclosed |
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-31 | — | — | US | disclosed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3191486-B1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031623-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | KMT2A 1894/4885MEN1 4776/4885MPO 2/4885 |
| US-20170247343-A1 | THIOETHER TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | KMT2A 1894/4885MEN1 4776/4885MPO 2/4885 |
| US-10981879-B2 | Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | KMT2A 1894/4885MEN1 4776/4885MPO 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.